{"id":"brallobarbital","rwe":[],"tags":[{"label":"brallobarbital","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ucedorm","offLabel":[],"synonyms":["brallobarbital calcium","brallobarbital","allylbromoallylbarbituric acid","brallobarbitone","ucedorm","vesperone"],"timeline":[],"brandName":"Ucedorm","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"brallobarbital","explanation":"Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Ucedorm is thought to either enhance or reduce the activity of these messengers, which can have a range of effects on the body. This can lead to changes in things like mood, sleep, and pain perception.","oneSentence":"Ucedorm works by affecting the activity of neurotransmitters in the brain, which can influence various physiological processes.","technicalDetail":"Brallobarbital is a barbiturate that acts as a GABA_A receptor agonist, which can lead to increased inhibitory neurotransmission and a range of downstream effects on the central nervous system."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/393","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BRALLOBARBITAL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:01:48.201416","biosimilars":[],"competitors":[],"genericName":"brallobarbital","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005441","UNII":"D0N7A2M3MU","CHEBI":"CHEBI:135188","INN_ID":"8","UMLSCUI":"C0054022","ChEMBL_ID":"CHEMBL2106093","PUBCHEM_CID":"68416","SECONDARY_CAS_RN":"61112-39-8","MESH_SUPPLEMENTAL_RECORD_UI":"C012790"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ucedorm, also known as brallobarbital, is a small molecule drug of the barbiturate class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating the activity of neurotransmitters in the brain. Ucedorm is not FDA-approved for any indications, and its commercial status, including whether it is patented or generic, is also unknown. As a result, there is limited information available on its safety profile, half-life, and bioavailability. Further research is needed to fully understand the properties and potential uses of Ucedorm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}